BioXpress Therapeutics SA is a premier partner for high-quality biosimilar monoclonal antibodies for unmet need indications such as cancer, inflammation and autoimmunity, including adaptive immunity. We have made a commitment to be your partner of choice for the full development of your biosimilar biol...
Originator BioXpress Therapeutics Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Orphan...
Trastuzumab biosimilar - BioXpress Therapeutics Alternative Names: BX-2318; BXT-2318 Latest Information Update: 28 Dec 2024 Price : €55 * Buy Profile Note: Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may vary according ...
别名: XpressBio上海代理 分子式: XpressBio北京代理 包装规格: XpressBio中国代理 xpressbio制造商和市场的分子和免疫学产品和服务to the生物科学研究社区环游世界。我们的客户are some of the*的制药、生物技术、政府和学术机构,环游世界。 我们制造抗体检测ELISA试剂immunoassays and for在小鼠,大鼠,豚鼠,仓鼠,...
别名:XpressBio试剂盒产品 产地:美国 品牌:XpressBio试剂盒产品 分子式:敬请咨询 包装规格:盒 货号:TPB-0211-2096 是否进口:是 北京百奥创新科技有限公司提供XpressBio试剂盒产品,更多XpressBio品牌产品,如细胞因子、抗体、试剂盒等,敬请咨询! XpressBio试剂盒部分产品列表: ...
XpressBio manufactures ELISA immunoassays and PCR controls for the Health Monitoring of Laboratory Animals (Rodents, Rabbit, Non-Human Primates, Cats and Dogs).
上海起发实验试剂有限公司XpressBio专业代理,具体产品信息欢迎电询:4006551678 产品型号: 厂商性质:经销商 更新时间:2024-09-01 访 问 量:1728 产品咨询联系我们 产品分类 Product Category 代理品牌 试剂耗材 查看全部 详细介绍 世界*实验材料供应商XpressBio正式授权上海起发为其中国代理,XpressBio在一直是行业的*,...
Xpressbio公司生产的动物健康监测ELISA试剂盒可检测所有常见的病原菌,如MHV、TMEV、PVM、仙台病毒EDIM及MAD等。该公司同时可定制独特的ELISA多病原菌检测试剂盒,在一个板孔中最多可以同时检测6种不同的病原菌。该公司同时还提供HIV,cDNA文库以及端粒酶检测产品。同时提供实验动物所涉及的所有常见病原菌的PCR相关产品...
Xpressbio公司生产的动物健康监测ELISA试剂盒可检测所有常见的病原菌,如MHV、TMEV、PVM、仙台病毒EDIM及MAD等。该公司同时可定制独特的ELISA多病原菌检测试剂盒,在一个板孔中最多可以同时检测6种不同的病原菌。该公司同时还提供HIV,cDNA文库以及端粒酶检测产品。同时提供实验动物所涉及的所有常见病原菌的PCR相关产品...
It states that AET Biotech will be responsible for providing further investment in the long term financing of biosimilars. According to AET's managing director Harm Peters, the BioXpress team has an impressive record in the development of the initial originator MAbs....